confidential treatment requested by codexis, inc. page 1 of 3 12th december 2018 th nestec ltd. avenue nestle 55 1800 vevey switzerland attention : [ * * * ] re : section 7. 3. 2 of the global development option and license agreement ( “ gdola ” ) dated october 12, 2017, as amended, by and between nestec ltd. ( “ nhsc ” ) and codexis, inc. ( “ codexis ” ) re : re : section 7. 3. 2 of the global development option and license agreement ( “ gdola ” ) dated october 12, 2017, as amended, by and between nestec ltd. ( “ nhsc ” ) and codexis, inc. ( “ codexis ” ) section 7. 3. 2 of the global development option and license agreement ( “ gdola ” ) dated october 12, 2017, as amended, by and between nestec ltd. ( “ nhsc ” ) and codexis, inc. ( “ codexis ” ) dear [ * * * ] this letter will confirm our agreement with respect to the achievement and payment of the solid dosage form development milestone of $ [ * * * ] as described in section 7. 3. 2 of the gdola and the conduct of a [ * * * ] study examining [ * * * ] and [ * * * ] of cdx - 6114 [ * * * ]. as of the date of this letter and subject to the terms and conditions of the gdola, notwithstanding anything to the contrary in section 7. 3. 2 or in exhibits f and g of the gdola, nhsc hereby agrees that within [ * * * ] after the achievement of the formulation objectives, nhsc shall pay to codexis [ * * * ]. codexis will complete the following deliverables in relation to the formulation objectives : ( a ) codexis delivers to nhsc [ * * * ]. ( b ) codexis delivers to nhsc [ * * * ]. ( c ) codexis delivers to nhsc [ * * * ]. ( d ) codexis delivers to nhsc [ * * * ]. ( e ) codexis delivers to nhsc [ * * * ]. ( f ) codexis delivers to nhsc [ * * * ]. upon receipt of the final deliverable from ( a ) to ( f ), as defined above, nhsc shall have [